WO2008136519A1 - Ep4アゴニストを含有してなる細胞傷害性t細胞の活性化剤 - Google Patents
Ep4アゴニストを含有してなる細胞傷害性t細胞の活性化剤 Download PDFInfo
- Publication number
- WO2008136519A1 WO2008136519A1 PCT/JP2008/058464 JP2008058464W WO2008136519A1 WO 2008136519 A1 WO2008136519 A1 WO 2008136519A1 JP 2008058464 W JP2008058464 W JP 2008058464W WO 2008136519 A1 WO2008136519 A1 WO 2008136519A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cytotoxic
- agonist
- cell activator
- microorganism
- infectious disease
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 title abstract 2
- 229940126530 T cell activator Drugs 0.000 title 1
- 208000035473 Communicable disease Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000002434 immunopotentiative effect Effects 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 244000005700 microbiome Species 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200880023882A CN101686985A (zh) | 2007-05-08 | 2008-05-07 | 含有ep4激动剂的细胞毒性t细胞的活化剂 |
JP2009513028A JP5479092B2 (ja) | 2007-05-08 | 2008-05-07 | Ep4アゴニストを含有してなる細胞傷害性t細胞の活性化剤 |
EP20080764261 EP2147672A4 (en) | 2007-05-08 | 2008-05-07 | CYTOTOXIC T CELL ACTIVATOR WITH AN EP4 AGONIST |
BRPI0811306 BRPI0811306A2 (pt) | 2007-05-08 | 2008-05-07 | Ativador de célula t citotóxica compreendendo agonista ep4 |
AU2008246579A AU2008246579A1 (en) | 2007-05-08 | 2008-05-07 | Cytotoxic T cell activator comprising EP4 agonist |
MX2009012043A MX2009012043A (es) | 2007-05-08 | 2008-05-07 | Activador de celulas t citotoxicas que comprende agonista ep4. |
US12/599,194 US8507545B2 (en) | 2007-05-08 | 2008-05-07 | Cytotoxic T cell activator comprising EP4 agonist |
CA 2684922 CA2684922A1 (en) | 2007-05-08 | 2008-05-07 | Cytotoxic t cell activator comprising ep4 agonist |
IL201918A IL201918A0 (en) | 2007-05-08 | 2009-11-04 | Cytotoxic t cell activator comprising ep4 agonist |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007-123119 | 2007-05-08 | ||
JP2007123119 | 2007-05-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008136519A1 true WO2008136519A1 (ja) | 2008-11-13 |
Family
ID=39943622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/058464 WO2008136519A1 (ja) | 2007-05-08 | 2008-05-07 | Ep4アゴニストを含有してなる細胞傷害性t細胞の活性化剤 |
Country Status (13)
Country | Link |
---|---|
US (1) | US8507545B2 (ja) |
EP (1) | EP2147672A4 (ja) |
JP (2) | JP5479092B2 (ja) |
KR (1) | KR20100016299A (ja) |
CN (1) | CN101686985A (ja) |
AU (1) | AU2008246579A1 (ja) |
BR (1) | BRPI0811306A2 (ja) |
CA (1) | CA2684922A1 (ja) |
IL (1) | IL201918A0 (ja) |
MX (1) | MX2009012043A (ja) |
RU (1) | RU2009145280A (ja) |
WO (1) | WO2008136519A1 (ja) |
ZA (1) | ZA200907760B (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012144649A1 (en) * | 2011-04-19 | 2012-10-26 | Sucampo Ag | Method for modulating cytokine activity |
WO2013004291A1 (en) | 2011-07-04 | 2013-01-10 | Rottapharm S.P.A. | Cyclic amine derivatives as ep4 receptor agonists |
JP2013536183A (ja) * | 2010-07-30 | 2013-09-19 | アラーガン インコーポレイテッド | 皮膚修復のための化合物及び方法 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2488168A1 (en) | 2009-10-14 | 2012-08-22 | Gemmus Pharma Inc. | Combination therapy treatment for viral infections |
US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
BR112013021035A2 (pt) | 2011-02-17 | 2016-10-11 | Allergan Inc | composições e métodos de reposição de tecido macio aperfeiçoados |
WO2013105997A2 (en) | 2011-02-23 | 2013-07-18 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
WO2013090552A1 (en) * | 2011-12-13 | 2013-06-20 | Yale University | Compositions and methods for reducing ctl exhaustion |
WO2013123275A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
EP2814510A1 (en) | 2012-02-16 | 2014-12-24 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
WO2013123274A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
WO2013123270A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
EP3176162B1 (en) | 2012-07-19 | 2020-05-27 | Cayman Chemical Company, Inc. | Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions |
US9676712B2 (en) | 2013-03-15 | 2017-06-13 | Cayman Chemical Company, Inc. | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
SG11201507470WA (en) | 2013-03-15 | 2015-10-29 | Cayman Chemical Co Inc | Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions |
CN105392505A (zh) | 2013-07-19 | 2016-03-09 | 开曼化学股份有限公司 | 用于促进骨生长的方法、系统和组合物 |
AU2014305843B2 (en) | 2013-08-09 | 2019-08-29 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
WO2015109112A1 (en) * | 2014-01-16 | 2015-07-23 | Gemmus Pharma Inc. | Combination treatment of antibiotic and gpcr agonist for viral/bacterial co-infections |
US20200368223A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Methods for inhibiting phosphate transport |
Citations (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS503362B1 (ja) | 1970-06-10 | 1975-02-04 | ||
JPS5231404B1 (ja) | 1971-04-28 | 1977-08-15 | ||
JPS6152146B2 (ja) | 1981-03-20 | 1986-11-12 | Ono Pharmaceutical Co | |
JP2000001472A (ja) | 1998-04-16 | 2000-01-07 | Ono Pharmaceut Co Ltd | 3,7―ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤 |
WO2000003980A1 (fr) | 1998-07-15 | 2000-01-27 | Ono Pharmaceutical Co., Ltd. | DERIVES DE PHENYL-POSTAGLANDINE E 5-THIA-φ-SUBSTITUES, PROCEDE DE PRODUCTION DESDITS DERIVES ET MEDICAMENTS CONTENANT LESDITS DERIVES EN TANT QUE PRINCIPE ACTIF |
WO2001037877A1 (fr) * | 1999-11-24 | 2001-05-31 | Ono Pharmaceutical Co., Ltd. | Medicaments pour des affections liees a la perte de masse osseuse |
WO2001062708A1 (fr) | 2000-02-22 | 2001-08-30 | Ono Pharmaceutical Co., Ltd. | Derives d'acide benzoique, procede de production desdits derives, et medicament contenant ces derives comme principe actif |
WO2002042268A2 (en) | 2000-11-27 | 2002-05-30 | Pfizer Products Inc. | Ep4 receptor selective agonists in the treatment of osteoporosis |
WO2003008377A1 (en) | 2001-07-16 | 2003-01-30 | F. Hoffmann-La Roche Ag | Prostaglandin analogues_as ep4 receptor agonists |
WO2003007941A1 (en) | 2001-07-16 | 2003-01-30 | F. Hoffmann-La Roche Ag | 2 pyrrolidone derivatives as prostanoid agonists |
WO2003009872A1 (en) | 2001-07-23 | 2003-02-06 | Ono Pharmaceutical Co., Ltd. | Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient |
WO2003035064A1 (en) | 2001-10-23 | 2003-05-01 | Applied Research Systems Ars Holding N.V. | Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors |
WO2003053923A2 (en) | 2001-12-20 | 2003-07-03 | Applied Research Systems Ars Holding N.V. | Pyrrolidine derivatives as prostaglandin modulators |
WO2003103664A1 (en) | 2002-06-06 | 2003-12-18 | Merck Frosst Canada & Co. | 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases |
WO2004063158A1 (en) | 2003-01-10 | 2004-07-29 | F.Hoffmann-La Roche Ag | 2-piperidone derivatives as prostaglandin agonists |
WO2004065365A1 (ja) * | 2003-01-21 | 2004-08-05 | Ono Pharmaceutical Co., Ltd. | 8−アザプロスタグランジン誘導体およびその医薬用途 |
WO2004085431A1 (en) | 2003-03-26 | 2004-10-07 | Merck Frosst Canada Ltd. | Prostaglandin analogs as ep4 receptor antagonists |
WO2005012232A2 (en) | 2003-07-18 | 2005-02-10 | Applied Research Systems Ars Holding N.V. | Hydrazide derivatives as prostaglandin receptors modulators |
US20050049227A1 (en) | 2003-08-28 | 2005-03-03 | Allergan, Inc. | Cyclohexyl prostaglandin analogs as EP4-receptor agonists |
WO2005100339A1 (en) | 2004-04-09 | 2005-10-27 | Allergan, Inc. | 10-hydroxy-11-dihydroprostaglandin analogs as selective ep4 agonists |
WO2005116010A1 (en) | 2004-05-26 | 2005-12-08 | Merck Frosst Canada Ltd. | Ep4 receptor agonist, compositions and methods thereof |
WO2006014207A1 (en) | 2004-07-02 | 2006-02-09 | Allergan, Inc. | Prostaglandin analogs |
WO2006014206A1 (en) | 2004-07-02 | 2006-02-09 | Allergan, Inc. | Prostaglandin analogs |
WO2006016689A1 (ja) * | 2004-08-10 | 2006-02-16 | Ono Pharmaceutical Co., Ltd. | Ep4アゴニストを含有してなる下部尿路系疾患の予防および/または治療剤 |
WO2006052892A1 (en) | 2004-11-05 | 2006-05-18 | Pepsico, Inc. | Enhanced barrier packaging for oxygen sensitive foods |
WO2006052630A1 (en) | 2004-11-04 | 2006-05-18 | Allergan, Inc. | Therapeutic substituted piperidone compounds |
WO2006055481A1 (en) | 2004-11-16 | 2006-05-26 | Allergan , Inc. | 2,3,4-substituted cyclopentanones as therapeutic agents |
WO2006058063A1 (en) | 2004-11-23 | 2006-06-01 | Allergan, Inc. | 2,3,4-substituted-cyclopentanones as therapeutic agents |
WO2006080323A1 (ja) | 2005-01-27 | 2006-08-03 | Asahi Kasei Pharma Corporation | ヘテロ6員環化合物及びその用途 |
WO2006113571A2 (en) | 2005-04-18 | 2006-10-26 | Allergan, Inc. | Substituted cyclopentanones for treating inflammatory bowel disease |
US20060252742A1 (en) | 2005-05-06 | 2006-11-09 | Allergan, Inc. | Therapeutic substituted beta-lactams |
WO2006137472A1 (ja) | 2005-06-24 | 2006-12-28 | Taisho Pharmaceutical Co., Ltd. | プロスタグランジン誘導体 |
JP2007023028A (ja) * | 2005-06-16 | 2007-02-01 | Ono Pharmaceut Co Ltd | 内耳疾患治療剤 |
WO2007014462A1 (en) | 2005-08-03 | 2007-02-08 | Merck Frosst Canada Ltd. | Ep4 receptor agonist, compositions and methods thereof |
WO2007014454A1 (en) | 2005-08-03 | 2007-02-08 | Merck Frosst Canada Ltd. | Ep4 receptor agonist, compositions and methods thereof |
JP3879785B2 (ja) | 1997-05-20 | 2007-02-14 | 日東電工株式会社 | キラーt細胞賦活剤 |
WO2007088190A1 (en) | 2006-02-03 | 2007-08-09 | Glaxo Group Limited | Benzo (f) isoindol-2-ylphenyl acetic acid derivatives as ep4 receptor agonists |
WO2007143825A1 (en) | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Indoline amide derivatives as ep4 receptor ligands |
WO2008012344A1 (en) | 2006-07-28 | 2008-01-31 | Glaxo Group Limited | Naphthalene derivatives used as ep4 receptor agonists |
WO2008012347A1 (en) | 2006-07-28 | 2008-01-31 | Glaxo Group Limited | Benzo [f] isoindoles as ep4 receptor agonists |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1442744B1 (en) * | 1999-08-10 | 2006-12-20 | Glaxo Group Limited | EP4 receptor ligand and use against neuropathic pain, colon cancer, HIV and migrane |
AU2003211574A1 (en) * | 2002-03-05 | 2003-09-16 | Ono Pharmaceutical Co., Ltd. | 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient |
JP4754820B2 (ja) * | 2002-06-10 | 2011-08-24 | メルク セローノ ソシエテ アノニム | プロスタグランジン作動薬としてのγラクタムおよびその使用 |
US20050003533A1 (en) * | 2003-05-08 | 2005-01-06 | Pawel Kalinski | Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use |
CA2566506A1 (en) * | 2004-06-01 | 2005-12-15 | Innogenetics N.V. | Peptides for inducing a ctl and/or htl response to hepatitis c virus |
WO2008058766A1 (en) * | 2006-11-16 | 2008-05-22 | Bayer Schering Pharma Aktiengesellschaft | Ep2 and ep4 agonists as agents for the treatment of influenza a viral infection |
-
2008
- 2008-05-07 EP EP20080764261 patent/EP2147672A4/en not_active Withdrawn
- 2008-05-07 WO PCT/JP2008/058464 patent/WO2008136519A1/ja active Application Filing
- 2008-05-07 MX MX2009012043A patent/MX2009012043A/es not_active Application Discontinuation
- 2008-05-07 CA CA 2684922 patent/CA2684922A1/en not_active Abandoned
- 2008-05-07 CN CN200880023882A patent/CN101686985A/zh active Pending
- 2008-05-07 JP JP2009513028A patent/JP5479092B2/ja not_active Expired - Fee Related
- 2008-05-07 US US12/599,194 patent/US8507545B2/en not_active Expired - Fee Related
- 2008-05-07 BR BRPI0811306 patent/BRPI0811306A2/pt not_active IP Right Cessation
- 2008-05-07 RU RU2009145280/15A patent/RU2009145280A/ru not_active Application Discontinuation
- 2008-05-07 AU AU2008246579A patent/AU2008246579A1/en not_active Abandoned
- 2008-05-07 KR KR1020097023236A patent/KR20100016299A/ko not_active Application Discontinuation
-
2009
- 2009-11-04 IL IL201918A patent/IL201918A0/en unknown
- 2009-11-04 ZA ZA200907760A patent/ZA200907760B/xx unknown
-
2013
- 2013-12-03 JP JP2013250375A patent/JP2014074042A/ja not_active Withdrawn
Patent Citations (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS503362B1 (ja) | 1970-06-10 | 1975-02-04 | ||
JPS5231404B1 (ja) | 1971-04-28 | 1977-08-15 | ||
JPS6152146B2 (ja) | 1981-03-20 | 1986-11-12 | Ono Pharmaceutical Co | |
JP3879785B2 (ja) | 1997-05-20 | 2007-02-14 | 日東電工株式会社 | キラーt細胞賦活剤 |
JP2000001472A (ja) | 1998-04-16 | 2000-01-07 | Ono Pharmaceut Co Ltd | 3,7―ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤 |
WO2000003980A1 (fr) | 1998-07-15 | 2000-01-27 | Ono Pharmaceutical Co., Ltd. | DERIVES DE PHENYL-POSTAGLANDINE E 5-THIA-φ-SUBSTITUES, PROCEDE DE PRODUCTION DESDITS DERIVES ET MEDICAMENTS CONTENANT LESDITS DERIVES EN TANT QUE PRINCIPE ACTIF |
WO2001037877A1 (fr) * | 1999-11-24 | 2001-05-31 | Ono Pharmaceutical Co., Ltd. | Medicaments pour des affections liees a la perte de masse osseuse |
WO2001062708A1 (fr) | 2000-02-22 | 2001-08-30 | Ono Pharmaceutical Co., Ltd. | Derives d'acide benzoique, procede de production desdits derives, et medicament contenant ces derives comme principe actif |
WO2002042268A2 (en) | 2000-11-27 | 2002-05-30 | Pfizer Products Inc. | Ep4 receptor selective agonists in the treatment of osteoporosis |
WO2003008377A1 (en) | 2001-07-16 | 2003-01-30 | F. Hoffmann-La Roche Ag | Prostaglandin analogues_as ep4 receptor agonists |
WO2003007941A1 (en) | 2001-07-16 | 2003-01-30 | F. Hoffmann-La Roche Ag | 2 pyrrolidone derivatives as prostanoid agonists |
WO2003009872A1 (en) | 2001-07-23 | 2003-02-06 | Ono Pharmaceutical Co., Ltd. | Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient |
WO2003035064A1 (en) | 2001-10-23 | 2003-05-01 | Applied Research Systems Ars Holding N.V. | Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors |
WO2003053923A2 (en) | 2001-12-20 | 2003-07-03 | Applied Research Systems Ars Holding N.V. | Pyrrolidine derivatives as prostaglandin modulators |
WO2003103664A1 (en) | 2002-06-06 | 2003-12-18 | Merck Frosst Canada & Co. | 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases |
WO2004063158A1 (en) | 2003-01-10 | 2004-07-29 | F.Hoffmann-La Roche Ag | 2-piperidone derivatives as prostaglandin agonists |
WO2004065365A1 (ja) * | 2003-01-21 | 2004-08-05 | Ono Pharmaceutical Co., Ltd. | 8−アザプロスタグランジン誘導体およびその医薬用途 |
WO2004085431A1 (en) | 2003-03-26 | 2004-10-07 | Merck Frosst Canada Ltd. | Prostaglandin analogs as ep4 receptor antagonists |
WO2004085430A1 (en) | 2003-03-26 | 2004-10-07 | Merck Frosst Canada Ltd. | Prostaglandin analogs as ep4 receptor agonists |
WO2005012232A2 (en) | 2003-07-18 | 2005-02-10 | Applied Research Systems Ars Holding N.V. | Hydrazide derivatives as prostaglandin receptors modulators |
WO2005023267A1 (en) | 2003-08-28 | 2005-03-17 | Allergan, Inc. | Cyclohexyl prostaglandin analogs as ep4-receptor agonists |
US20050049227A1 (en) | 2003-08-28 | 2005-03-03 | Allergan, Inc. | Cyclohexyl prostaglandin analogs as EP4-receptor agonists |
WO2005100339A1 (en) | 2004-04-09 | 2005-10-27 | Allergan, Inc. | 10-hydroxy-11-dihydroprostaglandin analogs as selective ep4 agonists |
WO2005116010A1 (en) | 2004-05-26 | 2005-12-08 | Merck Frosst Canada Ltd. | Ep4 receptor agonist, compositions and methods thereof |
WO2006014207A1 (en) | 2004-07-02 | 2006-02-09 | Allergan, Inc. | Prostaglandin analogs |
WO2006014206A1 (en) | 2004-07-02 | 2006-02-09 | Allergan, Inc. | Prostaglandin analogs |
WO2006016689A1 (ja) * | 2004-08-10 | 2006-02-16 | Ono Pharmaceutical Co., Ltd. | Ep4アゴニストを含有してなる下部尿路系疾患の予防および/または治療剤 |
WO2006052630A1 (en) | 2004-11-04 | 2006-05-18 | Allergan, Inc. | Therapeutic substituted piperidone compounds |
WO2006052892A1 (en) | 2004-11-05 | 2006-05-18 | Pepsico, Inc. | Enhanced barrier packaging for oxygen sensitive foods |
WO2006055481A1 (en) | 2004-11-16 | 2006-05-26 | Allergan , Inc. | 2,3,4-substituted cyclopentanones as therapeutic agents |
WO2006058063A1 (en) | 2004-11-23 | 2006-06-01 | Allergan, Inc. | 2,3,4-substituted-cyclopentanones as therapeutic agents |
WO2006080323A1 (ja) | 2005-01-27 | 2006-08-03 | Asahi Kasei Pharma Corporation | ヘテロ6員環化合物及びその用途 |
WO2006113571A2 (en) | 2005-04-18 | 2006-10-26 | Allergan, Inc. | Substituted cyclopentanones for treating inflammatory bowel disease |
US20060252742A1 (en) | 2005-05-06 | 2006-11-09 | Allergan, Inc. | Therapeutic substituted beta-lactams |
JP2007023028A (ja) * | 2005-06-16 | 2007-02-01 | Ono Pharmaceut Co Ltd | 内耳疾患治療剤 |
WO2006137472A1 (ja) | 2005-06-24 | 2006-12-28 | Taisho Pharmaceutical Co., Ltd. | プロスタグランジン誘導体 |
WO2007014462A1 (en) | 2005-08-03 | 2007-02-08 | Merck Frosst Canada Ltd. | Ep4 receptor agonist, compositions and methods thereof |
WO2007014454A1 (en) | 2005-08-03 | 2007-02-08 | Merck Frosst Canada Ltd. | Ep4 receptor agonist, compositions and methods thereof |
WO2007088190A1 (en) | 2006-02-03 | 2007-08-09 | Glaxo Group Limited | Benzo (f) isoindol-2-ylphenyl acetic acid derivatives as ep4 receptor agonists |
WO2007143825A1 (en) | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Indoline amide derivatives as ep4 receptor ligands |
WO2008012344A1 (en) | 2006-07-28 | 2008-01-31 | Glaxo Group Limited | Naphthalene derivatives used as ep4 receptor agonists |
WO2008012347A1 (en) | 2006-07-28 | 2008-01-31 | Glaxo Group Limited | Benzo [f] isoindoles as ep4 receptor agonists |
Non-Patent Citations (6)
Title |
---|
"molecular design", vol. 7, 1991, HIROKAWA SHOTEN, article "the development of medicine", pages: 163 - 198 |
CANCER RESEARCH, vol. 66, 2006, pages 10136 - 10144 |
NATURE MEDICINE, vol. 9, 2003, pages 744 - 749 |
PROCEEDINGS OF THE NATURAL ACADEMY SCIENCES OF USA, vol. 97, 2000, pages 371 - 376 |
See also references of EP2147672A4 |
THE JOURNAL OF LABORATORY AND CLINICAL MEDICINE, vol. 140, 2002, pages 92 - 102 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013536183A (ja) * | 2010-07-30 | 2013-09-19 | アラーガン インコーポレイテッド | 皮膚修復のための化合物及び方法 |
WO2012144649A1 (en) * | 2011-04-19 | 2012-10-26 | Sucampo Ag | Method for modulating cytokine activity |
JP2014511825A (ja) * | 2011-04-19 | 2014-05-19 | スキャンポ・アーゲー | サイトカイン活性の調節方法 |
WO2013004291A1 (en) | 2011-07-04 | 2013-01-10 | Rottapharm S.P.A. | Cyclic amine derivatives as ep4 receptor agonists |
Also Published As
Publication number | Publication date |
---|---|
ZA200907760B (en) | 2010-07-28 |
KR20100016299A (ko) | 2010-02-12 |
EP2147672A4 (en) | 2011-11-02 |
JP5479092B2 (ja) | 2014-04-23 |
CA2684922A1 (en) | 2008-11-13 |
CN101686985A (zh) | 2010-03-31 |
US8507545B2 (en) | 2013-08-13 |
US20100216689A1 (en) | 2010-08-26 |
IL201918A0 (en) | 2010-06-16 |
RU2009145280A (ru) | 2011-06-20 |
JP2014074042A (ja) | 2014-04-24 |
EP2147672A1 (en) | 2010-01-27 |
JPWO2008136519A1 (ja) | 2010-07-29 |
BRPI0811306A2 (pt) | 2015-01-27 |
MX2009012043A (es) | 2010-02-18 |
AU2008246579A1 (en) | 2008-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008136519A1 (ja) | Ep4アゴニストを含有してなる細胞傷害性t細胞の活性化剤 | |
WO2008054676A3 (en) | Medical devices and methods of using the same | |
WO2008055037A3 (en) | Infusion devices and methods | |
ZA200807767B (en) | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient | |
GB2451769B (en) | Devices, systems, and methods for medicament delivery | |
WO2010060937A3 (en) | Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor | |
WO2009031106A3 (en) | Use of a combination of hesperidin and of a microorganism for influencing the barrier function of the skin | |
WO2008036144A3 (en) | Nanoshells on polymers | |
EP2447282A3 (en) | Anti-CD22 Antibodies, their Immunoconjugates and uses thereof | |
WO2006138418A3 (en) | Improvement of cognitive performance with sirtuin activators | |
WO2008113011A3 (en) | Virus like particle purification | |
CL2012001080A1 (es) | Dispersión sólida de rifaximina y un portador farmacéuticamente aceptable; composición farmacéutica; uso en el tratarmiento y/o prevención de una infecciíon microbiana que comprende la administración de la dipersión sólida. | |
EP1998751A4 (en) | Devices, systems and methods for medicament delivery | |
EP1985283A4 (en) | GELPENDING COMPOSITION FOR USE IN MEDICINE, APPARATUS FOR THE APPLICATION OF THE COMPOSITION, AND MEDICAMENT-RELATED TAX CARRIER | |
EP2030615A3 (en) | Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases | |
WO2006131806A3 (en) | Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release | |
BRPI0913175A2 (pt) | artigo antibalístico, e, uso do mesmo. | |
WO2006121522A3 (en) | Implantable sensors and pumps, anti-scarring agents, and therapeutic compositions | |
WO2010045407A3 (en) | Reduction of infection associated with medical device | |
EP1731609A4 (en) | INHIBITOR OF THE EXPRESSION OF RAD51, MEDICAMENT CONTAINING THE INHIBITOR AS ACTIVE INGREDIENT AND USE THEREOF | |
WO2007081716A3 (en) | Self-illuminating quantum dot systems and methods of use thereof | |
EP2166015A4 (en) | LINCOSAMIDE DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING ACTIVE SUBSTANCE | |
SI2151439T1 (sl) | Nitrogeniran aromatski derivat s 6-členskim obročem in farmacevtsko sredstvo, ki obsega ta derivat | |
WO2008101672A3 (en) | Agent for use in the case of fructose intolerance | |
WO2008097364A3 (en) | Use of oritavancin for prevention and treatment of anthrax |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880023882.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08764261 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2009513028 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2684922 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008246579 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 20097023236 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 581006 Country of ref document: NZ Ref document number: 12599194 Country of ref document: US Ref document number: MX/A/2009/012043 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008764261 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2008246579 Country of ref document: AU Date of ref document: 20080507 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009145280 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: PI0811306 Country of ref document: BR Kind code of ref document: A2 Effective date: 20091109 |